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Eph receptors and their ephrin ligands were identiﬁed in the late 1980’s. Subsequently, they were linked to diﬀerent physiological
and pathophysiological processes like embryonic development, angiogenesis, and tumorigenesis. In this regard, recent work
focused on the distribution and eﬀects of Eph receptors and ephrins on tumor cells and tumor microenvironment. The
purpose of this review is to outline the role of these molecules in physiological angiogenesis and pathophysiological tumor
angiogenesis. Furthermore, novel therapeutical approaches are discussed as Eph receptors and ephrins represent attractive targets
for antiangiogenic therapy.
1.EphReceptorsandEphrins
1.1. Structure and Signaling. Eph receptors were identiﬁed
in the late 1980’s [1] and are known as largest family of
receptor tyrosine kinases. They consist of a glycosylated
extracellular domain with the immunoglobulin-like ligand-
binding site, followed by a cysteine-rich region and two
ﬁbronectin type III repeats (Figure 1). Connected via a
single transmembrane spanning domain, the intracellular
region contains a juxtamembrane domain, a tyrosine kinase
domain, a sterile alpha motif, and a PDZ-(Postsynaptic
density 95-Discs large-Zonula occludentes-1) binding motif
[1, 2]. Eph receptors bind membrane bound ligands, the
ephrins, and both, receptors and ligands, are divided into
two subclasses A or B based on binding properties and
structural homologies. Class A ephrins are membrane-
bound via a glycosylphosphatidylinositol anchor and class
B ephrins contain a transmembrane domain and a short
cytoplasmic region with conserved tyrosine residues and
a PDZ-binding motif. Class A Eph receptors preferentially
bind all A-type ephrins and class B Eph receptors bind all B-
type ligands. However, there are some exceptions, as EphA1
primarily binds ephrinA1, EphA4 binds both, A- and B-
type ligands, and ephrinA5 binds EphA receptors as well as
EphB2 (Figure 2)[ 3–6]. Until today, 15 diﬀerent receptors
and 9 ligands are known (https://eph-nomenclature.med
.harvard.edu/table 1.html).
In contrast to other receptor tyrosine kinases, Eph
receptors/ephrins show unique properties in their activation
and signaling. For the activation of the receptors not only
dimerization as in most receptor tyrosine kinases is required
but also multimerization of the ligands [7]. Multimer-
induced signaling seems to be diﬀerent from signals of
normal dimers in so far as the degree of multimerization
of the ephrins accounts for the kind and strength of
biological eﬀects [8]. As Eph receptors bind ligands which
are also membrane bound, cell-cell contact is needed for
Eph receptor activation. On the other hand, recent work
demonstrated that at least A-type ephrins can be released
from the cell surface [9, 10]. These soluble proteins were
shown to be functionally active and possibly represent an
additional signaling mechanism without mandatory cell
contact. Nevertheless, Eph receptor/ephrin signaling can
also proceed bidirectionally, “forward” and “reverse” [11–
13]. “Forward signaling” involves binding of ephrins by the
appropriate Eph receptor. This leads to autophosphorylation
of intracellular tyrosine residues of the Eph receptor and
further to activation of diﬀerent downstream signal trans-
duction cascades [14, 15]. In the case of B-type ephrins,
signaling can also take place “reverse”, if the cytoplasmic2 Journal of Oncology
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Figure 1: Structure of Eph receptors and ephrin ligands. PDZ:
Postsynaptic density 95-Discs large-Zonula occludentes-1-protein,
GPI: glycosylphosphatidylinositol.
tail of the ephrin is phosphorylated which also results
in activation of diﬀerent signaling cascades. Moreover, it
should be noted that ephrinA ligands might also have
the potency to reverse signaling (overview in [4]). Many
studies of the last decade indicate a complex cross-talk
between Eph receptors/ephrins and other signaling pathways
which is necessary for consistent biological functions. The
interactionsbetweenEphreceptors/ephrinsanddiﬀerentcell
surface receptors, adhesion molecules, channels, pores, and
cell surface proteases are reviewed in [16].
Taken together, Eph receptors and their appropriate
ephrin ligands represent an essential communication system
that directs cell motility, repulsion and adhesion, cell-cell
and cell-matrix contacts in a number of biological processes.
Due to the focused topic of this article, only two of them,
angiogenesis and tumor angiogenesis, should be elucidated
in detail, while other processes will be outlined in brief.
1.2. Embryonic and Neural Development. Eph receptor/
ephrin signaling plays a crucial role in embryonic develop-
ment [17]. As an example, it has been shown that altered
expression of EphA3 and ephrinA5 leads to defects in gastru-
lation and somite development [18]. Furthermore, together
with integrin-α5 and ﬁbronectin, Eph receptors/ephrins are
discussed to mediate mesenchymal-to-epithelial transition
and, hence, formation of somite boundaries [19].
EphA4
EphA3
EphA1
Eph 
receptors
Ephrin
ligands
EphrinA1
EphrinA3
EphrinA4
EphrinA5
EphrinA6
EphrinB1
EphrinB2
EphrinB3
EphrinA2 EphA2
EphA5
EphA6
EphA7
EphA8
EphA9
EphB1
EphB2
EphB3
EphB4
EphB5
EphB6
Figure 2: Major interactions of Eph receptors and ephrin ligands.
A further role of Eph receptor/ephrin signaling is sug-
gested in the developing and adult vertebrate brain. Due
to their complementary expression pattern, EphA4, EphB2,
EphB3, and their B-type ligands are implicated in the for-
mation of rhombomere boundaries. Thereby, bidirectional
signaling seems to be required for the restriction of cell
intermingling between neighboring rhombomeres [20, 21].
Furthermore, many studies analyzed the involvement of Eph
receptor/ephrin signaling in neuronal growth cone collapse,
leading to axon guidance by inhibition [17]. For instance,
studies on EphA4- and ephrinB3-null mice indicated that
both proteins are required for normal formation of the corti-
cospinal tract ﬁbres, whereby Eph receptor forward signaling
is mandatory [22, 23] .T h ei m p o r t a n c eo fp r o p e re p h r i n
ligand expression for correct outgrowth of retinal ganglion
cell axons was analyzed by Hornberger and colleagues.
They demonstrated that unscheduled overexpression of
ephrinA2 in temporal axons leads to insensitivity of guiding
outgrowing axons of the caudate tectum by repulsion [24].
In the development of the visual system it was shown
that EphB2 and EphB3 receptors and B-type ephrins are
involved in axon pathﬁnding of retinal ganglion cells to
the optic disc and that deletion of both EphB2 and EphB3
leads to increased frequency of axon guidance errors in
this model [25]. Furthermore, the EphB2 receptor is also
involved in synaptic functions (synaptic plasticity) in the
adult mammalian central nervous system [26, 27]. In this
regard, Henderson and colleagues found that mice lacking
the EphB2 receptor show reduced synaptic N-methyl-D-
aspartate-mediated current and reduced long-term potenti-
ation in hippocampal and dentate gyrus synapses [28].
1.3. Tumorigenesis. Eph receptor/ephrin signaling plays not
only a role in physiological processes, but also in pathophysi-
ological processes such as tumorigenesis [7, 29]. Thus, many
ephrins and Eph receptors were found to be upregulated
in several human carcinomas such as breast, colon, liver,
prostate, and melanoma and are often associated with tumorJournal of Oncology 3
progression and metastasis (for overview see [7, 29–31]). On
the other hand, also downregulation of Eph receptors can
lead to increased metastasis and carcinogenesis as shown for
EphA1 in colorectal cancer, EphA7 in prostate carcinomas,
and EphB6 in melanoma [32–34]. Thereby, Eph receptors do
not operate like classical oncogenic growth factor receptors,
because their activation does only in exceptional cases
inﬂuence proliferation of the tumor cells [35, 36]. Rather
dysregulation of Eph receptor activity seems to eﬀect cell-
matrix attachment, cell-cell attachment, organization of
the cytoskeleton, and modiﬁcation of tumor cell survival,
which could result in increased cellular motility, tumor cell
invasion, and metastasis. Cell-matrix attachment can be
inﬂuenced by Eph receptors via modulating the integrin
activity. For instance, EphA2 stimulation with ephrinA1
leads to decreased focal adhesion kinase (FAK) phosphory-
lation which further results in inactive conformation of inte-
grins and, ﬁnally, inhibition of integrin-mediated adhesion,
cell spreading, and migration [37]. It is assumed that also
small GTPases of the Ras and Rho family could be linked
to decreased integrin activation and cellular adhesion [38].
However, the modiﬁcation of cell attachment is probably
dependent on the Eph receptor/ephrin ligand ratio. A high
expression of Eph receptor and low expression of ephrin
ligand could represent an “advantage” for tumor growth
and metastasis [29]. A possible cause for imbalanced Eph
receptor/ephrin ratio was recently analyzed by Winter and
colleagues who identiﬁed binding sites of multiple mRNA-
stabilizing and destabilizing factors at the 3’UTR sequences
of Eph/ephrin transcripts. They found that binding of HuR
protein (a member of the embryonic lethal abnormal vision
family of RNA-binding proteins [39]) to these regions
destabilized Eph/ephrin transcripts in tumor cell lines
[40].
The interaction of Eph receptors and ephrins with other
adhesion molecules such as E-cadherin could inﬂuence cell-
cell attachment. Thereby, it is assumed that E-cadherin
can inﬂuence the expression and cellular localization of
Eph receptors and vice versa [41–43]. The modiﬁcation
of the cytoskeleton is another important prerequisite for
enhanced cellular motility and invasion, respectively, and
there exists evidence of involvement of Eph receptor/ephrin
signaling. For instance, EphA3/ephrinA5 signaling induces
growth cone collapse in retinal ganglion cells and cell
rounding, blebbing, and detachment in EphA3-expressing
human kidney epithelial cells and melanoma cell lines [44,
45]. In both studies it could be shown that Rho kinase is
involved in the observed eﬀects. This was further conﬁrmed
by Cliﬀord and colleagues, who demonstrated that EphA3
receptor suppresses motility through regulation of Rho
GTPases in rhabdomyosarcoma cell lines [46]. Moreover,
Eph/ephrin signaling can inﬂuence cell survival as shown
recently by Feng and colleagues. They demonstrated that
overexpression of ephrinA2 in hepatocellular carcinoma
cells leads to enhanced tumor cell survival and proved
that this is caused by resistance to tumor necrosis factor-
α-(TNF-α-) induced apoptosis [47]. In this regard, Holen
et al. demonstrated in Jurkat TAg cells that signaling
through ephrinA induced activation of Scr and Akt kinases,
resulting in inhibition of antigen receptor-induced apop-
tosis [48]. Finally, it should be noted that some reports
describe functionally relevant Eph receptor mutations in
some tumor entities. For instance, mutations have been
identiﬁed in EphA3 in melanoma and glioblastoma, and
EphA3, EphA4, EphA7, and EphB6 in colorectal cancers
[49, 50].
2. Angiogenesis
Angiogenesis is deﬁned as growth of new blood vessels
by sprouting from existing vessels [51, 52]. The lumen of
blood vessels is faced by a single-layer squamous epithelium
consisting of endothelial cells (ECs) which is separated from
the circumjacent outer layers by the basal membrane. In
small vessels (e.g., venules) ECs are enclosed by pericytes,
in larger vessels by elastin ﬁbres, smooth muscle cells and
connective tissue. On one hand, ECs participate in the
generation of blood vessels during embryonic development;
on the other hand, they retain their ability to proliferation
and migration in adult organisms, where they renew the
inner wall of existing blood vessels and rebuild new ves-
sels, for instance, in uterus mucosa during menstruation
and wound healing. At the beginning of the formation
of a new capillary ECs form lateral pseudopodia which
develop to a hollow tube. This new capillary sprout expands
until it meets another capillary sprout for fusion, result-
ing in blood ﬂow. This process is regulated by diﬀerent
expression of surface molecules on arterial and venous
capillaries.
Angiogenesis is activated by signals from the target
tissues. The reaction of the ECs spans four periods: secre-
tion of proteases to cleave the basal membrane of the
parental capillary, migration of ECs towards the signal,
proliferation of ECs, and, ﬁnally, formation of tubes and
diﬀerentiation of the ECs. Activating signals are soluble
factors whose receptors are localized predominantly on ECs.
The most important factor is vascular endothelial growth
factor (VEGF) and its regulator hypoxia-inducing factor
(HIF-1α), which stimulates transcription of the VEGF gene
[51, 53]. Other important growth factors, like acidic and
basic ﬁbroblast growth factor (aFGF, bFGF), can also initiate
angiogenesis, whereby they aﬀect not only ECs but also
othercelltypes[51].AdditionalvascularECs-speciﬁcgrowth
factors involve four members of the angiopoetin family and
at least one member of the ephrin family, whereby those
factorshavetooperatehighlycoordinatedtoformfunctional
vessels. Finally, factors not speciﬁc for ECs are required
such as platelet-derived growth factor (PDGF) and tumor
growth factor-β (TGF-β)[ 54]. Generally, it is assumed that
VEGF functions as initiator of angiogenesis in development
and adult organisms (with formation of immature vessels),
followed by angiopoetin-1 and ephrinB2 function, necessary
for maturation and stabilization of the vessel [54]. Moreover,
angiogenesis is regulated not only by activating signals
but also by inhibitors, for instance, thrombospondin-1,
interferon-α,plateletfactor-4,andangiostatin.Todate,more
than 20 inducers or inhibitors of angiogenesis have been
identiﬁed [51].4 Journal of Oncology
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Concerning Eph/ephrin signaling in angiogenesis, the pair of
EphB4/ephrinB2 seems to play a key role. They are assumed
to deﬁne vascular borders due to their reciprocal distri-
bution: ephrinB2 on arteries and EphB4 on veins already
in early developmental stages [55–57]. The expression of
ephrinB2 persists until late embryogenesis and adulthood,
with distribution expanding from arterial ECs to surround-
ing smooth muscle cells and pericytes [54, 58]. Generally,
interplay between ECs and perivascular supporting cells
mediated by ephrinB2/Eph signaling is critical for vascular
development as shown in several studies [30]. For instance,
Foo and colleagues demonstrated that vascular smooth
muscle cells require ephrinB2 for normal association with
small-diameter blood vessels [59]. In this context, Oike et
al. showed that unscheduled ubiquitous ephrinB2 expression
in mice development leads to sudden death in embryonic
stages due to defective recruitment of vascular smooth
muscle cells to the ascending aorta [60]. Simultaneously, the
authorssuggestthatbidirectionalsignalingismandatoryand
that cell-to-cell repellent eﬀects are important comparable
to their role in the development of the central nervous
system. In this regard, F¨ uller et al. hypothesized that distinct
propulsive and repulsive eﬀector functions of endothelial
ephrinB2 and EphB4 prevent intermingling of cells and
mediate spatial position signals during angiogenesis and
vessel assembly [61]. The importance of reverse signaling
through ephrinB2 for vascular development is outlined by
Adams et al. and analyzed in detail by Salvucci et al.,
who found that phosphorylation at the intracellular domain
of ephrinB is dependent of Src kinases and is assumed
to play a role in pericyte-to-ECs assembly into vascular
structures [62, 63]. Additionally, migration and proliferation
of ECs were analyzed by Steinle et al., who found that
stimulation of EphB4 receptors with ephrinB2-Fc fragments
leads to phosphorylation of Akt kinase and, furthermore,
to increased proliferation and migration of the ECs. The
authors show that this is mediated by the phosphatidylinos-
itol 3-kinase/Akt/endothelial nitric-oxide synthase/protein
kinase G/mitogen-activated protein kinase axis [64].
Beside EphB4/ephrinB2 other B-class Eph and ephrins
play a role in vascularization and angiogenesis. In this
regard, ephrinsB1, B3, and EphB2, B3, B4 are required for
the regulation of the formation of the vascular network
during cardiovascular development and for vascularization
processes in the female reproductive system [65–67]. Fur-
thermore, ephrinB1 is assumed to mediate ECs attachment
on extracellular matrix by activation of integrins [68].
In the case of A-class Eph/ephrins, mainly EphA2 and
ephrinA1 seem to be important for angiogenic processes.
For instance ephrinA1 is expressed in vascular develop-
ment during embryogenesis in murine endocardium, dorsal
aorta and primary head veins and later in intersomitic
vessels and the limb bud vasculature [69]. This implicates
that ephrinA1 expression corresponds to regions of vas-
culogenesis and/or angiogenesis, and presumably enhances
angiogenesis [55, 69]. Additional studies illuminated the
role of involved pathways. Referring to this, the role of
VEGF was analyzed by Cheng et al., who demonstrated
that soluble EphA2-Fc receptors inhibited VEGF-induced
survival, migration, sprouting of ECs and corneal angio-
genesis [70]. The authors furthermore show that TNF-α
induced ephrinA1 expression on ECs. This was found to
be mediated by JNK and p38MAPK signaling pathways,
leading to ECs migration and blood vessel assembly [71].
Another study showed that interaction of ephrinA1 with
EphA2 induced activation of PI3 kinase and Rac1 GTPase
leading to ECs aggregation and migration [72]. The role of
EphA2/ephrinA1 in adult angiogenesis was further analyzed
by diﬀerentinvitrostudies.Forinstanceitwasdemonstrated
that ephrinA1 enhanced assembly of human umbilical
venous endothelial cells (HUVEC) in matrigel and that
soluble EphA2-Fc receptors inhibited microvessel formation
in a rat aortic ring assay [73, 74].
3. Tumor Angiogenesis
Angiogenesis can occur not only in physiological conditions
but also in abnormal processes such as tumorigenesis. It is
an early- to midstage event in many human cancers and a
crucial step for the transition of a small, harmless cluster of
mutated tumor cells into a large, malignant growth, capable
of spreading to other organs throughout the body [75].
Without angiogenesis tumor size is restricted due to lack
of nutrients, growth factors, and oxygen, resulting in coun-
terbalance of dying and proliferating cells. Hypoxia in solid
tumorsoccursatadistanceof ≥70μmfromfunctionalblood
vessels and it is generally accepted that tumors do not exceed
av o l u m eo f1 - 2m m 3 without the induction of angiogenesis
[51, 76]. Tumor angiogenesis starts with the appearance
of proteins that promote neovascularization (angiogenesis).
Such proteins are produced by tumor cells themselves or
by inﬁltrating immune cells, such as macrophages [77].
Alternatively,angiogenic proteins canbe mobilized bytumor
cells from the nearby tissue. Once the process is initiated it
cannot be controlled or even stopped by the malignant cells
[75]. Instead, newly dividing ECs release diﬀerent proteins
thatcanstimulatetheproliferationormotilityoftumorcells,
leading to support of metastasis.
Generally, tumor cells produce two types of protein: one
kind stimulates angiogenesis the other inhibits it, which
lead to the hypothesis of an angiogenic switch in tumor
angiogenesis [51, 76]. The most prominent angiogenic
inducers are bFGF, aFGF, and VEGF with their corre-
sponding receptors on ECs and among inhibitors are α-
Interferon, platelet factor-4, and thrombospondin-1 [51].
FGF and other angiogenic factors can be sequestered in the
extracellular matrix of many cell types, for instance ECs,
and is believed to be released by proteolytic degradation of
the extracellular matrix [51, 78]. For inhibitors alternative
storage mechanisms are described: they are assumed to be
stored as cryptic parts of larger molecules that are not per se
inhibitors.Amongthemarea29kDafragmentofﬁbronectin
[79], a 16kDa fragment of prolactin [80, 81], angiostatin
as fragment of plasminogen [82], a small fragment of
platelet factor-4 [83], a propeptide of type 1 collagen [84],
and a peptide fragment of endothelial growth factor [85].
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determines whether the tumor can switch on angiogenesis,
whereby tumor angiogenesis is preferentially induced by a
lossordecreaseintheproductionofinhibitors.Nevertheless,
the underlying mechanisms are still poorly understood and
dysregulation of transcription or the activation of diﬀerent
proteases are under discussion.
An alternative way to facilitate tumor perfusion indepen-
dent of tumor angiogenesis is the concept of vasculogenic
mimicry [86, 87]. Thereby it is assumed that tumor cells
re-express endothelial and mesenchymal markers, normally
appearing on embryonic cells. This is accompanied by
induction of vascular structures mimicking blood vessels
and thus promoting tumor growth. For instance, metastatic
melanoma cells are able to constitute channels ﬁlled with
blood cells. This tubules exhibit a basal lamina but no ECs
and the formation seems not to be dependent of bFGF, TGF-
β, VEGF, PDGF, TNF-α, hypoxia, or integrins [87, 88]. In
consequence,theformationoftubularnetworksononehand
results in better supply with nutrients and oxygen, on the
other hand it can facilitate the invasion of tumor cells into
the blood ﬂow, thus, promoting metastasis [89]. Although
the underlying mechanisms are not fully understood, the
involvement of receptor tyrosine kinases, especially Eph
receptors, is strongly suggested. In an in vitro study Hess
and colleagues showed that transient knockout of EphA2
expressioninaggressiveuvealmelanomatumorcellsresulted
in inhibition of tubular network formation [88]. Further the
authors found that phosphorylation of EphA2 by ephrinA1
leads to activation of downstream signaling kinases such as
FAK and PI3 kinase and, furthermore, to the formation of
vessel-like networks [90].
3.1. Role of Eph Receptors and Ephrins in Tumor Angiogenesis.
TheﬁrstreportsconcerningadirectconnectionbetweenEph
receptor/ephrin signaling and tumor angiogenesis appeared
approximately 10 years ago. Nikolova and colleagues investi-
gated the B-class Eph receptors and ephrins and found a spa-
tially, temporarily, and hormonally coordinated expression
of EphB4 and ephrinB2 during normal mouse mammary
morphogenesis. The receptor was predominantly localized
in the myoepithelial cells surrounding the ducts and alveoli
whereas ligand expression was limited to the luminal epithe-
lial cells [91]. The disruption of the balanced expression
lead to onset of carcinogenesis with loss of ligand expression
and shift of receptor expression from myoepithelial cells sur-
rounding the ducts to ECs with progressive malignancy [91].
The importance of EphB4/ephrinB2 in tumor angiogenesis
and tumor growth was also demonstrated in recent work on
mouse models. In this regard, Kimura and colleagues found
that soluble ephrinB2-Fc molecules suppressed growth of
head and neck squamous cell carcinoma xenografts by
inducing maturation of vessels in the tumor [92]. Other
studiesinvestigatingtheeﬀectsofEphB4/ephrinB2ontumor
microvasculature, tumor growth, and survival of tumor cells
indicated that EphB4 could act as a survival advantage in
headandnecksquamouscellcarcinomaandinbreastcancer,
respectively [93, 94]. Class A molecules were analyzed by
Ogawa et al. using two xenograft models from human breast
cancer and Kaposi sarcoma. They found both ephrinA1
and EphA2 expressed in tumor cells and endothelial cells
in these xenografts, and also in vasculature and tumor
cells of surgically removed human cancers [95]. A further
study revealed EphA2, in combination with VEGF, to be
overexpressed in squamous cell carcinoma of oral tongue
and, therefore, implicated in malignancy [96]. Today it is
known that Eph receptors and ephrins are expressed in
both tumor cells and tumor vasculature of many types of
cancer, often at higher levels than in endogenous tissue
[30]. Thereby, Eph receptor activation (forward signaling)
is important as demonstrated by diﬀerent studies using
soluble receptors. Blocking EphA receptor signaling using
soluble EphA2-Fc and EphA3-Fc receptors decreased tumor
vascular density, tumor volume and cell proliferation in
vivo, suggesting that the soluble receptors inhibited blood
vessel recruitment by the tumor [74, 97, 98]. Furthermore,
EphA2 kinase function in the tumor microenvironment
seems necessary not only for tumor angiogenesis but also for
metastatic progression [99, 100].
Nevertheless, reverse signaling through ephrins is
another important factor in tumor angiogenesis. Expression
of truncated, soluble EphB4 receptor in breast cancer cells in
a mouse xenograft model (with ephrinB2 ligand primarily
expressed in the vasculature) increased tumor angiogenesis,
suggesting that soluble EphB4 promotes tumor growth
by stimulating angiogenesis through ephrinB2 signaling
[101]. Another study showed that EphB4 and ephrinB2 are
expressed by ECs of human malignant brain tumors and
overexpression of diﬀerent EphB4 variants in blood vessels
in tumor xenografts leads to the assumption that EphB4 acts
as negative regulator of blood vessel branching and vascular
network formation [102]. The involvement of additional
Eph receptors in the switch of dormant tumors to the fast-
growing angiogenic phenotype was analyzed recently by
Almog and colleagues, who found increased EphA5 plasma
levels in mice and, furthermore, that mRNA levels in tumor
specimens of glioma patients correlated with disease stage.
Hence, among other investigated molecules, EphA5 receptor
possibly could represent a novel early cancer biomarker
[103].
An important question remains unanswered, concerning
theinitiationofthealteredEphreceptor/ephrinexpressionin
tumor cells and tumor vasculature. Until now it is not fully
understood which mechanisms lead to this dysregulation,
but it is hypothesized that hypoxia could play a role in
this context. For instance in a mouse skin ﬂap model
of hypoxia Vihanto and colleagues showed that hypoxia
upregulates not only HIF-1α and VEGF but also EphB4,
ephrinB2, EphA2 and ephrinA1 both on mRNA and protein
levels up to 48 hours after induction of hypoxia [30,
104]. Furthermore, transcriptional proﬁles of umbilical cord
blood and bone marrow-derived stem and progenitor cells
showed that EphA3 gene (among many other genes) is
upregulated after hypoxia [105]. Another study, using HIF-
2α knockdown mice showed that also HIF-2α interacts in
hypoxia-induced tumor vascularization through activation
of at least ephrinA1 [106]. In contrast, in neonatal rats
exposed to chronic hypoxia, among others, expression of
HIF-2α and ephrinA1 was downregulated [107]. However,6 Journal of Oncology
it remains an important ﬁeld and the identiﬁcation of
regulating mechanisms could provide novel targets for anti-
angiogenic cancer therapies.
4. Therapeutical InterventionsTargeting Eph
ReceptorsandEphrinLigands
In contrast to many other therapeutic approaches, anti-
angiogenic therapy does not aim to destroy tumor cells
directly. Instead, it prevents tumor growth by its insuﬃcient
supply with nutrients and oxygen as a result of omitted
blood vessel formation [75]. Numerous small molecule
inhibitors and neutralizing antibodies targeting regulators
of angiogenesis such as VEGF/VEGF receptors are recently
under development and in clinical evaluation [108]. For
instance, recently the Food and Drug Administration of
the U.S.A. approved the anti-VEGF-A-neutralizing antibody
Bevacizumab for treatment of stage III-IV colorectal cancer
in combination with chemotherapy and for treatment of
n o n s q u a m o u sn o n - s m a l lc e l ll u n gc a n c e r s ,a sw e l la ss m a l l
moleculetyrosinekinaseinhibitorsfortreatmentofrenalcell
cancer (Sorafenib, Sunitinib) and hepatocellular carcinoma
(Sorafenib) [109]. As Eph receptors and ephrins are also sig-
niﬁcantly involved in angiogenesis and tumor angiogenesis
and, therewith, in tumor progression and metastasis, they
represent important targets for cancer therapy [19, 30].
To date, there are diﬀerent approaches to target Eph
receptors and/or ephrins, either extracellularly by preventing
receptor-ligand interactions or intracellularly through inhi-
bition of tyrosine kinases or modiﬁcation of gene transcrip-
tion or translation (Figure 3). One of them is the application
of monoclonal antibodies, which show high speciﬁcity and
are already well established tools in tumor therapy. The ﬁrst
ones were directed against EphA2 and showed a signiﬁcant
inhibition of tumor growth in vitro [110, 111]. Furthermore,
eﬀective targeting and internalizing into antigen-positive
tumors in diﬀerent mouse xenograft models have been
reported for EphA3 and EphB2 monoclonal antibodies
[112, 113]. Although the speciﬁcity for a particular binding
partner is probably limited, another approach with great
potential represents blocking of the Eph receptor/ephrin
signaling between tumor cells and ECs by the introduction
of soluble Eph receptors. In this regard, it was demon-
strated that soluble monomeric EphB4 receptor resulted
in dramatically reduced tumor growth in mouse models
[114, 115]. Furthermore, Scehnet and colleagues fused the
extracellular domain of EphB4 with human serum albumin
for blocking ephrinB2 which results in inhibited migration
and invasion of Kaposi sarcoma cells in response to various
growth factors [116]. In addition, the role of A-class Eph
receptors was analyzed and inhibition of tumor angiogenesis
and suppressed tumor growth in vivo was demonstrated
for soluble EphA2-Fc and EphA3-Fc receptors [74, 97, 98].
Not only Eph receptors but also ephrins show therapeutic
potency as truncated soluble forms. In this regard, soluble,
monomeric ephrinA1 is a functional ligand for EphA2 in
glioblastoma multiforme and modulates processes relevant
totheprogressionofmalignancy[10].Beyondtumorpathol-
ogy,solubleephrinB2-FcorEphB4-Fcchimeras,respectively,
and soluble ephrinB2 were shown to reduce pathologic neo-
vascularization in the retina [117, 118]. Moreover, a possible
therapeutic strategy represents conjugation of ephrins to
gold-coated silica nanoshells, which was used to selectively
target prostate tumor cells [119]. An alternative strategy for
targeting Eph receptor/ephrin signaling is the application of
mimetic or antagonist peptides, which were generated so far
for A-class as well as for B-class Eph receptors [120–123].
Finally, an alternative “extracellular” strategy is described by
Yamaguchi and colleagues who investigated peptide-pulsed
dendritic cell vaccines and found that immunization with
dendritic cells pulsed with EphA2-derived peptides inhibited
tumor growth in vivo in EphA2-positive murine colorectal
adenocarcinomas [124].
Therapeutical strategies focusing on intracellular struc-
tures involve inhibitors, selective for a single or for multiple
tyrosine kinases. In this regard, several 2,5-dimethylpyrrolyl
benzoic acid derivatives have been generated as selective
small molecule inhibitors for EphA4 receptors, as well as 2,4-
bis-anilinopyrimidines for the inhibition of EphB4 receptors
[125–127]. In addition, various N-substituted 3-amino-
4-methylbenzamide based type II kinase inhibitors were
analyzed concerning their potency to inhibit EphB2 receptor
[128]. A well-characterizedmultiple-targeted tyrosine kinase
inhibitor is dasatinib. It is a dual Src/Abl kinase inhibitor,
whereby FAK, Crk-associated substrate, and EphA2 receptor
are assumed as additional targets. The inhibitor shows
potent anti-proliferative activity against hematologic malig-
nancies [129] and has recently been approved for treatment
of all stages of chronic myelogeneous leukemia [130].
Beneath its therapeutic eﬀects in leukemias it was shown
that dasatinib blocks migration and invasion of human
melanoma cells without aﬀecting proliferation and survival
[130]. Furthermore, it was demonstrated that dasatinib
blocks growth, migration and invasion of breast cancer
cells [131], induced apoptosis and inhibited proliferation
and invasion in diﬀerent ovarian cancer cell lines [132]. Of
importance, dasatinib also showed therapeutic potency to
inhibit EphA2 in pancreatic cancer [133]. An additional con-
ceivable approach for therapies directed against intracellular
targets is the regulation of the gene expression using small
interfering RNA or antisense oligodeoxynucleotides. In this
regard,Kumaretal.demonstratedthatknockdownofEphB4
expression leads to anti-tumoral eﬀects in breast cancer in
vitro and in vivo [93]. Furthermore, it was demonstrated
that knockdown of EphA2 suppressed ephrinA1- and VEGF-
inducedendothelialcellmigrationandinhibitedcellprolifer-
ationandinducedapoptosisinhumangliomacells[70,134].
In part the pharmacological approaches against Eph
receptor-/ephrin-mediated tumor angiogenesis discussed
above also provide the possibility to develop strategies for
imaging of tumor vascularization, for instance, by means of
ﬂuorescent-orradiolabeled-smallmoleculekinaseinhibitors
or peptide ligands.
Overall, diﬃculties targeting Eph receptor/ephrin signal-
ing in cancer therapy should be kept in mind. Heterogenous
expression patterns of various Eph receptors/ephrins in
tumor and normal tissue complicate the discrimination of
malignantcellsfromnonmalignantcells[135].Furthermore,Journal of Oncology 7
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the eﬀects of Eph receptor-targeting agents on normal
epithelial cells are insuﬃciently analyzed until today [136].
Another limitation in targeting Eph receptors represents
the occasional opposing eﬀects of one Eph receptor as
t u m o rs u p p r e s s o ra n dt u m o rp r o m o t e r[ 136]. In this
regard, signaling of ephrinA1 and tumor cell-speciﬁc EphA2
suppresses processes like growth and migration, whereas
interaction of ephrinA1 with ECs-speciﬁc EphA2 seems to
stimulate these same eﬀects [137]. Furthermore, the eﬃcacy
of EphA2 antibody-based therapy may depend on tumor
type as no suppressive eﬀect on tumor growth was observed
in a colorectal tumor model [138], whereas mice harboring
ErbB2 in mammary epithelium were sensitive to therapeutic
inhibition of EphA2 [139]. When targeting the Eph kinase
activity, it should be noted that inhibition is useful in tumors
where kinase activity promotes tumorigenesis (melanoma)
but may instead be ineﬀective or even detrimental for the
treatment of other types of cancer where Eph receptor
signaling suppresses tumorigenesis [136]. In addition, the
binding promiscuity of Eph receptors and ephrin ligands
as well as their capability to bidirectional signaling will
further complicate targeting strategies and increase the
potential for adverse side eﬀects. Therapies designed to
either activate or block an Eph receptor may also alter
the signaling function of the ligand in adjacent cells [136,
140]. After all, possible interactions of Eph receptor/ephrin
therapeutic agents with other agents should be consid-
ered. It is assumed, that the kinase inhibitor imatinib can
counteract the anti-oncogenic eﬀects of EphB4 agonists
in breast cancer [136]. On the other hand, chemothera-
peutic agents that target ErbB receptors may enhance the
eﬀects of EphB4-targeted therapies [136]. Despite and due
to the mentioned limitations it is necessary to under-
stand the complex functions of Eph receptors/ephrins in
homeostasis and tumor progression to avoid undesirable
side eﬀects or unintentional exacerbation of disease func-
tions [30]. In this regard, targeting Eph receptor/ephrin
signaling to inhibit tumor angiogenesis and, therewith,
tumor growth represents a promising approach in ﬁghting
cancer.8 Journal of Oncology
5. Conclusion
Eph receptors and their ligands, the ephrins, form a complex
cellular communication system. Its complexity is based on
the large number of diﬀerent receptor and ligand molecules,
their promiscuous binding properties, the ability to bidi-
rectional signaling, formation of multimers, and crosstalk
with other signaling pathways and molecules. An intricacy,
we just begin to understand. Eph receptors and ephrins
are involved in embryonic development, development of
the nervous system, angiogenesis and also in tumorigenesis
and tumor angiogenesis, respectively. They mediate cell-
cell repellent eﬀects, cell-cell and cell-matrix attachment,
they inﬂuence cell survival and cytoskeleton dynamics,
aﬀecting cell motility, which could further result in tumor
progression, invasion and metastasis. In the last decade Eph
receptors and ephrin ligands were put in perspective to anti-
tumoralandanti-angiogenictherapy.Todate,manydiﬀerent
therapeutic strategies targeting Eph receptors or ephrins
are pursued and hopefully result in improvement of cancer
treatment in the near future.
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